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(0.42% vs. 0.79%) reduction in rates of AAA-related mortality and rupture, respec-
tively, as compared to the standard ultrasound strategy. During an 8-year follow-up 
period, the higher cost of elective surgeries by the PSU strategy was partially offset by 
lower rates and costs of emergency surgeries compared to the standard ultrasound 
strategy. The higher screening rate with the PSU strategy resulted in a cost savings of 
c17 per screened eligible male over 8 years (annualized c2/year). Sensitivity analyses 
demonstrated reductions in deaths and aortic ruptures ranging from 17% to 50% and 
2% to 73%, respectively, at a maximum cost-savings of c7 to c50, and only one 
instance of an incremental cost of c3 per eligible patient over 8 years. CONCLU-
SIONS: Use of a PSU device to screen for AAA may reduce deaths, aortic ruptures, 
and surgery costs with a savings of c2/year per screened eligible male.
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OBJECTIVES: Patients hospitalized for Heart Failure (HF) continue to have high 
re-admission and mortality rates in the 30 days following discharge. Cardiac param-
eters such as left ventricular function (LVF) and inferior vena cava (IVC) size are 
predictors of mortality and readmission, and are presently assessed by 2-dimensional 
echocardiography (2DE). Pocket-sized ultrasound (PSU) devices for LVF and IVC 
assessment offer potential advantages of lower cost, increased availability, and porta-
bility as compared to 2DE. The study objective was to develop a model to assess the 
clinical and economic impact of PSU versus 2DE for HF hospitalizations in Italy. 
METHODS: The model was developed from an Italian hospital perspective, and 
timeframe was during HF hospitalization to 30 days post-discharge. The clinical 
scenario evaluated the impact of LVF assessment on mortality, while the economic 
scenario incorporated the impact of IVC size on costs (2010 Euros). Our model 
assumed 100% of PSU patients would undergo evaluation, as compared to only 68% 
who currently undergo 2DE. We assumed abnormalities identiﬁ ed by PSU would 
require subsequent 2DE evaluation while lack of abnormalities would not require 
2DE. Model outputs of number of deaths, readmissions, and costs were calculated 
using a sample of 186,000 HF hospitalizations. One-way sensitivity analyses were 
conducted to evaluate the robustness of model outcomes. RESULTS: A PSU strategy 
yielded a 19.1% (7.2% vs. 8.1%) reduction in the 30-day mortality rate, as compared 
to the 2DE strategy, and a 33.4% (26.0% vs. 39.1%) reduction in 30-day readmis-
sions leading to a cost savings of c55 million (c297/ HF admission). Models were 
robust to changes in model inputs with reduction in deaths from 2–37%, and cost 
savings from c63–315 per HF admission. CONCLUSIONS: Use of a PSU device to 
visualize key cardiac parameters for HF hospitalizations in Italy may afford reduction 
in deaths and cost-savings.
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OBJECTIVES: To assess and compare direct in-hospital costs in patients hospitalized 
with acute coronary syndromes (ACS; unstable angina or myocardial infarction), acute 
heart failure (AHF) and acute coronary syndromes complicated by heart failure (ACS 
with AHF) from health care payer perspective. METHODS: Patients hospitalized from 
2005 to 2008 were classiﬁ ed in registry of Faculty Hospital Brno according to the 
clinical characteristics. Direct in-hospital costs (ﬂ at rate of admission and stay; medica-
tion and procedures) were evaluated in total 965 ACS (73% male; 64.7 years; 54% 
STEMI), 962 AHF (56% male; 70.8 years) and 808 AHF with ACS (62% male; 71.2 
years; 61% STEMI) patients. The severity of disease was qualiﬁ ed as need of intensive 
care (ICU days); the predictors of high cost were identiﬁ ed in all groups. (1c = 26CZK). 
RESULTS: Mean in-hospital cost was 101658CZK/3910c in ACS pts (length-of-stay 
5.6 days; 81% pts 2.3 ICU days; 0.3% died), 70201CZK/2700c in AHF pts (length-
of-stay 9 days; 48 % pts 4 ICU days; 11.4 % died) and 122340CZK/4705c in ACS 
with AHF (length-of-stay 7.2 days; 92% pts 3.5 ICU days; 19.2% died). Percutaneous 
coronary intervention with stenting (PCI) formed more than 80% of total cost in ACS 
patients (performed in 78% pts.; 91% STEMI; 62% non-STEMI) and almost 60% 
costs in ACS with AHF pts (performed in 66% pts; 84% STEMI; 39% non-STEMI); 
antiarrhythmic interventions (incl. ICD, CRT BiV or PM device) made almost 50% 
cost in AHF although carried out in 8.6% pts. CONCLUSIONS: According to in-
hospital costs patients with acute coronary syndromes complicated by heart failure 
were the most costly with maximum need of intensive care. Since 26.7% pts were 
transferred to other health care institution (e.g. 9% cardiosurgery) we expect the most 
signiﬁ cant increase of total amount of direct in-hospital costs in comparison with ACS 
(16.9% pts transferred) or AHF (11.5% pts transferred).
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OBJECTIVES: The TRITON-TIMI 38 Trial demonstrated that in patients with acute 
coronary syndromes (ACS) undergoing planned percutaneous coronary intervention 
(PCI), prasugrel compared to clopidogrel signiﬁ cantly reduced the rate of ischemic 
events over up to 15 months of follow-up, though there was an increased risk of major 
bleeding. Three risk factors for bleeding identiﬁ ed in the trial were a prior history of 
stroke/TIA, age ≥75 years, and body weight <60 kg. Patient-level data from TRITON 
was used to compare hospitalization costs in South Korea for patients without these 
risk factors for bleeding, who were randomized to prasugrel vs. clopidogrel. 
METHODS: Details regarding hospitalizations for all patients from 8 high enrolling 
countries (US, Australia, Canada, Germany, Italy, Spain, UK, France; n = 3373 pra-
sugrel, 3332 clopidogrel) were collected prospectively. The US diagnosis-related group 
codes were assigned to all hospitalizations, to which 2009 South Korean unit costs 
were applied. Estimates of incremental costs associated with PCI-associated peripro-
cedural MIs and PCI- and CABG-associated bleeding events were added separately, 
based on published U.S. data. RESULTS: Prasugrel was associated with a 17,723 
KRW per patient increase in costs due to bleeding, and an 8,377 KRW decrease in 
costs due to reduced periprocedural MI, during the index hospitalization. Per-patient 
costs from hospitalization for MI (not involving revascularization) during the follow-
up period were 291,022 KRW lower with prasugrel compared to clopidogrel, and 
costs associated with revascularization hospitalizations during follow-up were 
505,032 KRW lower. Costs from follow-up bleeding events were 52,082 KRW higher 
for prasugrel, while aggregate hospitalization costs were 293,656 KRW lower. CON-
CLUSIONS: For ACS patients with planned PCI, the lower ischemic event rate with 
prasugrel yields a reduction in overall hospitalization costs, despite increased costs 
from bleeding. These results have implications for the cost-effectiveness of alternative 
antiplatelet strategies for ACS patients undergoing PCI in South Korea.
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OBJECTIVES: To compare cardiovascular disease (CVD) associated costs between 
patients continuing statin (simvastatin 20 mg/day or equivalent) monotherapy (SM) 
or receiving adjunct therapy with niacin extended-release (NER) for comprehensive 
lipid management. METHODS: Secondary risk patients age ≥30 continuing SM or 
augmenting statin therapy with NER between January 1, 2005-November 30, 2008 
(index date) with ≥1 pre-index lipid panel (LDL-C < 100 mg/dL & HDL-C < 50 or 
<55 mg/dL for men & women, respectively) and no hepatic dysfunction were included. 
SM patients were matched 3:1 to NER patients based on prior exposure to statin. The 
primary outcome was total (medical and pharmacy) annual CVD-related costs. 
Medical and pharmacy costs consisted of inpatient, emergency room, and outpatient 
expenditures associated with CVD and pharmacy charges for anti-hyperlipidemic 
therapy. Outcome comparison between SM and NER and was conducted via general-
ized linear models via gamma distribution and log-link function. Multivariate analyses 
controlled for age, gender, geography, co-morbidities, and baseline lipids. RESULTS: 
A total of 728 patients were identiﬁ ed; 546 SM patients were matched to 182 NER 
patients. Compared to SM, there was no difference in baseline LDL-C (P = 0.13) or 
Deyo-Charlson co-morbidity Index scores (P = 0.77). Baseline HDL-C (35 ± 6 vs. 42 
± 7; P < 0.0001) was lower and TG (190 ± 98 vs. 153 ± 76; P < 0.0001) was higher 
among NER patients. While annual CVD-related pharmacy expenditure was higher 
for NER [mean (95% CI), $2261 ($1991–$2587) vs. $1276 ($1186–$1373)], adjusted 
and unadjusted medical costs were 69% (P = 0.0002) lower for NER ($542 ($378–
$799) vs. $1718 ($1373–$2149); P < 0.0001) vs. SM. Offsets in medical and pharmacy 
costs resulted in total annual CVD-related costs between NER and SM (($2796 
($2331–$3353) vs. $2988 ($2960–$3318); P = 0.5346). CONCLUSIONS: Therapy 
augmentation with NER for comprehensive lipid management was associated with 
reduced annual CVD-related medical expenditure leading to total annual CVD-related 
costs compared to statin monotherapy.
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OBJECTIVES: Compare the risk of subsequent coronary event (SCE), cerebrovascular 
event, and associated medical costs between patients maintaining statin monotherapy 
(SM) or augmenting statin with fenoﬁ brate (FF) after an acute coronary event (ACE). 
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METHODS: Patients with an ACE between January 1, 2004 and May 31, 2009 were 
identiﬁ ed (the Index Date was deﬁ ned as the earliest ACE). Patients age ≥18, ≥6 
months eligibility pre- and post-Index Date, ≥1 statin ﬁ ll and no statin augmenting 
ﬁ ll 6 months before the Index Date, and ≥1 FF or SM ﬁ ll 6 months after the Index 
Date (Cohort ID Period) were included. Patients with ﬁ lls for alternative statin aug-
menting therapies or SCE during the Cohort ID Period were excluded. The primary 
outcome was SCE. Secondary outcomes were cerebrovascular event risk and event-
related medical costs. Event risk was compared using Cox proportional hazards 
models, while costs were compared via generalized linear models. Multivariate analy-
ses controlled for age, gender, geography, co-morbidities, concomitant medications, 
statin potency, and severity of initial ACE. RESULTS: A total of 24,625 patients added 
FF (n = 399) or maintained SM (n = 24,226) 6-months after initial ACE while meeting 
study inclusion/exclusion criteria. FF patients were younger (59 ± 10 vs. 65 ± 12, P < 
0.0001), less likely female (27% vs. 34%, P = 0.002), and had shorter follow-up (358 
vs. 443 days, P < 0.0001). FF patients had lower frequency of SCE (20%) vs. SM 
(25%), with an unadjusted hazard ratio (HR) of 0.88 (95%CI: 0.71–1.10). a similar 
directional trend was observed for cerebrovascular events (HR: 0.74; 95% CI: 0.40–
1.37). Multivariate analyses of SCE risk demonstrated consistent directional beneﬁ t 
(HR: 0.93; 95% CI: 0.74–1.16). Clinical ﬁ ndings corresponded with 25% lower 
adjusted annual event-related costs compared to SM (0.75; 95% CI: 0.57—0.97; p = 
0.0306). CONCLUSIONS: The positive clinical beneﬁ ts from this real-world analysis 
provide evidence supporting ability of FF to reduce both SCE risk and event-related 
medical costs following ACE.
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OBJECTIVES: The aims of study were 1)to determine equivalent dosages of 
Rosuvastin(R) and Atorvastatin(A) in the treatment of dyslipidemia, and 2)to evaluate 
cost-effectiveness of R vs. A. METHODS: The R and a arms of 29 RCTs with stable 
dose treatments for minimum 6 weeks (n = 27.588) were included in the analysis. The 
arms with periods after titration or switch were excluded. The effectiveness parameters 
chosen were the pooled percent decrease in LDL-C, LDL/HDL, TC/HDL ratios and 
10-years’ cardiovascular risk (CVR) based on Wilson equation. Only medication costs 
were calculated for R and A, since other costs directly related with dyslipidemia were 
assumed to be same. Dose-effect relationship was analyzed by plotting linear regres-
sion line for R and A, separately. Incremental Cost-effectiveness Ratios (ICER) were 
calculated as added cost per percent decrease in lipid parameters and per absolute 
reduction in 10-years’ CVR. RESULTS: Equivalent clinical effectiveness of R was 
provided with 3.9-fold, 3.2-fold and 3.2-fold dosages of a in mg, in terms of percent 
decrease in LDL-C, LDL/HDL and TC/HDL ratios, respectively. Absolute 10-years’ 
CVR reductions with R5-40 mg and A10-80 mg were 4.5–6.9% and 3.7–5.7%, 
respectively. 1(R):2(A) dose pair was selected for cost-effectiveness analysis. The yearly 
medication costs were as follows: R5 mg vs. A10 mg (c113.67** vs. c128.03), 
R10 mg vs. A20 mg (c174.68 vs. 226.77c), R20 mg vs. A40 mg (c261.26 vs. 283.20c) 
and R40 mg vs. A80 mg (c261.26 vs. c294.68). R dominated a with regards to ICER 
for all effectiveness parameters. Sensitivity analysis proved that dominance of R was 
stable when the model was run for extreme values for R and a in the literature. 
CONCLUSIONS: In this analysis, R was found more efﬁ cacious than three times 
higher dose of A. R is more cost-effective than a in reducing LDL-C level, LDL-HDL 
and TC/HDL ratios and 10-years’ CVR reduction. **1 Euro = 1.9595TL
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OBJECTIVES: The objective of this study was to quantify, for the ﬁ rst time in a 
Spanish population, the time and cost burden of informal care for patients with heart 
failure. METHODS: A descriptive analysis of a multicenter, prospective observational 
study was performed. Patients who met inclusion criteria were followed-up for a 
period of 12 months, with 3 visits programmed at baseline, 6 months and 12 months. 
a total of 9 Spanish hospitals were involved in the study. Baseline characteristics and 
caregiver’s information were registered for every patient. Once identiﬁ ed total hours, 
the replacement cost method was used. RESULTS: A total of 450 patients were 
included, 76% men, mean age was 62.6 years. 66.1% were in NYHA class II, 32.7% 
NYHA class III and 1.1% NYHA class IV. Prevalence of ischemic cardiopathy was 
33.5%. Thirty-ﬁ ve percent of patients had an implantable device (ICD, RCT or 
pacemaker). One-third needed support for daily activities. One-hundred and one 
informal caregivers were identiﬁ ed, mean age of 57.6 years, mostly women (84.1%). 
Main relationship with caregiver was spouse/couple (74.2%), followed by son/daugh-
ter (16.6%). Number of weekly hours of caregiving was estimated at 42.5 hours 
(39.46 hours for patients NYHA class II and 47.39 hours for patients NYHA class 
III-IV) and shadow prices values from c9 to c12 per hour. Total costs associated to 
informal caregiving increases between c19,897 and c26,530 (c18,466–c24,621 for 
patients in NYHA class II and c22,178–c29,571 for patients in NYHA class III or 
IV). CONCLUSIONS: Approximately one-third required support from an informal 
caregiver, which represents a signiﬁ cant burden for society and often has not been 
accounted for in economic evaluations of treatments for heart failure. Costs for 
informal care appear to increase with worse disease severity as measured by NYHA 
class.
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OBJECTIVES: Acute coronary syndrome (ACS) is a highly prevalent disease and the 
third-leading cause of death in Korea, however the economic impact of ACS from 
societal perspective has not been investigated. This study examined the national epi-
demiology and economic costs of ACS in Korea for 2009. METHODS: This study 
used the societal cost of illness framework, consisting of epidemiology of ACS, direct 
medical costs, direct non-medical costs, and indirect costs such as productivity lost 
from morbidity and mortality of ACS. National-level health survey results and insur-
ance claim databases were used to analyze annual health care utilization, hospitaliza-
tion costs and outpatient costs of the total Korean population (48 million people). 
Using a data mining technique, we identiﬁ ed medical claims with international clas-
siﬁ cation of disease 10 codes for ACS over a one year period and estimated the costs 
by a macro-costing method. RESULTS: Prevalence rate of ACS is estimated at 6.4 
persons per 1000 population in 2009 and its mortality rate is 7.8% in 2008. During 
2009, there were 309,384 patients who had at least 1 medical claim related to ACS. 
The total societal cost of ACS in 2009 was estimated at $1.02 billion. Direct medical 
cost for ACS was $380.3 million, which includes hospitalization cost of $318.8 million 
and outpatient cost of $61.6 million. The direct non-medical cost, involving transpor-
tation cost and caregiver cost, was estimated at $10.1 million. Indirect costs associated 
with morbidity and mortality of ACS were $627.2 million. CONCLUSIONS: The 
study showed that the societal cost of ACS in Korea is markedly high, particularly the 
indirect cost, followed by hospitalization cost. Early and effective management of the 
disease is necessary to reduce mortality and morbidity of ACS. Findings of this study 
suggest for further research to uncover ways to reduce the economic burden of ACS 
in Korea.
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OBJECTIVES: Aneurysmal subarachnoid hemorrhage (SAH) is a cerebrovascular 
disease with a high mortality and severe disability. Longitudinal studies investigating 
health-economic burden and health-related quality of life (HRQoL) in SAH are scare 
and only one previous study analyzed cost-driving factors. The objective was to evalu-
ate HRQoL and ﬁ rst-year costs in German patients with aneurysmal SAH and to 
identify cost-driving factors. METHODS: A total of 113 incident cases of aneurysmal 
SAH treated in the Department of Neurosurgery and Neuroradiology at the University 
of Bonn between January 2004 and December 2005 were eligible for the study. Clini-
cal assessments (Hunt and Hess scale, Barthel Index), evaluation of HRQol (36-Item 
Short Form Survey, EQ5D, EQ-VAS) and collection of cost data from societal perspec-
tive (health-economic questionnaires) were performed at discharge, and at 6 and 12 
months follow-up. All costs are expressed in c (year 2009 values). Independent deter-
minants of costs and HRQoL were identiﬁ ed using multiple regression analysis. 
RESULTS: The total ﬁ rst-year costs were c38,300 (95%CI: 34,490–43,100) per 
patient. Direct costs accounted for 58.7% of total costs and were mainly paid by the 
health insurance (92.0%). The major cost-driving factors were younger age and worse 
functional outcome (Barthel-Index). HRQol in SAH patients was considerably 
reduced. At discharge, 92.2% of patients had moderate or severe problems on the 
EQ-5D. The EQ-VAS at discharge was 57.8 ± 19.3 and increased by only 12–14% 
after 12 months. Independent predictors of decreased HRQol were female gender, 
severe disease, depression, lower level of education and the lack of a stable partnership. 
CONCLUSIONS: Aneurysmal SAH is a cerebrovascular disease with considerable 
health-economic burden and unfavourable long-term HRQoL outcome. Clinical trials 
in SAH should include HRQol measures. Independent determinants of costs and 
HRQol identiﬁ ed in this study should be considered in the health care programmes 
aimed at increasing the HRQol in SAH survivors and decreasing health-economic 
burden of SAH.
